Concentration,unionization and the distribution of income in Canadian manufacturing industry

An attempt is made to assess how the unionization of labor and the presence of buyers possessing monopsony power affects the distribution of income among the factors of production in Canadian manufacturing. It is found that these variables have a composite effect. They transfer income from factors of production in one industry to the factors in another. They also affect the distribution of income between labor and capital within industries.     

Notes on a possible Bentham manuscript: a mystery unresolved

In the Works and Correspondence of David Ricardo (Volume x)Piero Sraffa noted that the Mill-Ricardo case of the RicardoPapers deposited at Cambridge contained ‘a paper probablyin Bentham's hand-wriring on the effects on profits of cultivatingsuccessive qualities of land'. In 1978 I made a search of theRicardo Papers and no such document was to be found. This notereports the discovery in Trinnity College Library—andprovides a trancription—of a document that may be theelusive item, though it is in James Mill's hand.     

Dr. Martin Bronfenbrenner (1914-1997): Scholar, Critic, Cynic, and Comrade-in-Arms

ABSTRACT Professor Martin Bronfenbrenner's mark on the economics profession was significant and worth remembering. He touched the lives of many as a father, cousin, teacher, scholar, expert referee, colleague, and judge of important contemporary debates. Of special interest is his unique personality. He was a specialist in self-effacement, peppered with liberal shakes of cynicism and sarcasm. Despite all this, he managed to win the respect and hearts of individuals on several continents and across several generations. This essay brings a small but diverse part of the story together in one place.     

Market structure and performance in intellectual property: The case of copyright collectives

Copyright collectives are associations to whom authors transfer copyrights for purposes of exploitation. These collectives grant licenses for the use of works in their repertory, they negotiate and collect royalties which they distribute to their members and they take legal actions against those who infringe the copyrights to which they hold title. This paper investigates the consequences of the formation of collectives on the number of copyrighted works produced and circulation of these works in the framework of a model of joint production. Welfare issues are also addressed.     

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin

Background:

For many years, the standard of care for patients diagnosed with deep vein thrombosis (DVT) has been low-molecular-weight heparin (LMWH) bridging to an oral Vitamin-K antagonist (VKA). The availability of new non-VKA oral anticoagulants (NOAC) agents as monotherapy may reduce the likelihood of hospitalization for DVT patients.

Objective:

To compare hospital visit costs of DVT patients treated with rivaroxaban and LMWH/warfarin.

Methods:

A retrospective claim analysis was conducted using the MarketScan Hospital Drug Database for care provided between January 2011 and December 2013. Adult patients using rivaroxaban or LMWH/warfarin with a primary diagnosis of DVT during the first day of a hospital visit were identified (i.e., index hospital visit). Based on propensity-score methods, historical LMWH/warfarin patients (i.e., patients who received LMWH/warfarin before the approval of rivaroxaban) were matched 4:1 to rivaroxaban patients. The hospital-visit cost difference between these groups was evaluated for the index hospital visit, as well as for total hospital-visit costs (i.e., including index and subsequent hospital visit costs).

Results:

All rivaroxaban users (n?=?134) in the database were well-matched with four LMWH/warfarin users (n?=?536). The mean hospital-visit costs were $5257 for the rivaroxaban cohort and $6764 in the matched-cohort of patients using LMWH/warfarin. The $1508 cost difference was statistically significant between cohorts (95% CI?=?[?$2296; ?$580]; p-value?=?0.002). Total hospital-visit costs were lower for rivaroxaban compared to LMWH/warfarin users within 1, 2, 3, and 6 months after index visit (significantly lower within 1 and 3 months, p-values <0.05)

Limitations:

Limitations were inherent to administrative-claims data, completeness of baseline characteristics, adjustments restricted to observational factors, and lastly the sample size of the rivaroxaban cohort.

Conclusion:

The availability of rivaroxaban significantly reduced the costs of hospital visits in patients with DVT treated with rivaroxaban compared to LMWH/warfarin.     

EURANDOM: a decade of European stochastics

Conception, founding, start-up and development of EURANDOM are described by Willem van Zwet, Frank den Hollander (former scientific directors of EURANDOM) and Wim Senden (former managing director of EURANDOM).